Abstracts Archive - Page 1651 of 2607 - ACR Meeting Abstracts

Abstract Number: 773 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis
Cristiane Medeiros¹, Luciana Seguro², Fernando Henrique Carlos de Souza², Nadia E Aikawa³ and Eloisa Bonfa⁴, ¹Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: The use of Rituximab (RTX) in patients with autoimmune diseases has been associated with an increased incidence of infection and risk factors for this…
Abstract Number: 774 • 2016 ACR/ARHP Annual Meeting
BIIB059, an Anti-BDCA2 Monoclonal Antibody, Demonstrates Acceptable Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects in a Phase 1 Study with Single Ascending Doses (SAD) in Healthy Volunteers
David Martin, Lauren Stevenson, Pratapa Prasad, Karen Smirnakis, Amy Kao, Dania Rabah, Wenting Wang and Nathalie Franchimont, Biogen, Cambridge, MA
Background/Purpose: Type I interferons (IFN-I) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). In SLE, immune complexes stimulate plasmacytoid dendritic cells (pDCs) to…
Abstract Number: 775 • 2016 ACR/ARHP Annual Meeting
Evaluation of Use of Belimumab in Clinical Practice Settings: Results in Argentina
Alejandra Babini¹, Mercedes Argentina García², Juan Carlos Barreira³, Bernado Pons-Estel⁴, Melitza Iglesias⁵ and Gabriela Streger⁶, ¹Hospital Italiano de Cordoba, Cordoba, Argentina, ²Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ³Hospital Britanico, Buenos Aires, Argentina, ⁴Sanatorio Parque, Rosario, Argentina, ⁵Medical Affairs, GlaxoSimthKline, Philadelphia, PA, ⁶Direccion Medica, GlaxoSmithKline, Buenos Aires, Argentina
Background/Purpose: Studying clinical effectiveness of belimumab treatment in real world clinical practice of Systemic Lupus Erythematosus (SLE) is relevant in assessing external validity of randomized…
Abstract Number: 776 • 2016 ACR/ARHP Annual Meeting
Eurolupus and Low Steroid Regimen in Proliferative Lupus Nephritis: Retrospective Evaluation of 38 Patients in the Black Population of Martinique
Charles Cartou¹, Katlyne Polomat², Florence MOINET², Serge ARFI³, Lauren Brunier-Agot⁴, Marie Blattery⁵, Aymeric Couturier⁶, Georges JEAN BAPTISTE⁷, Michel De Bandt⁸ and Christophe Deligny⁹, ¹nephrology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ²Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, ³University Hospital, CHU Fort de France, Fort de France, Martinique, ⁴Internal medicine and rheumatology, Zobda Quitman Hospital, Fort de France, Martinique, ⁵rheumatology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ⁶nephrology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ⁷RHEUMATOLOGY, CHU MARTINIQUE, FWI, Fort-de-France, Martinique, ⁸CHU Fort de France, Fort de France, France, ⁹Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique
Background/Purpose: There is no data on the efficacy of the EUROLUPUS regimen associated with initial low steroids daily dose in African descent patients with proliferative…
Abstract Number: 777 • 2016 ACR/ARHP Annual Meeting
a Singlecenter Experience of Rituximab Treatment in 86 Patients with Systemic Lupus Erythematosus
Bahar Artim-Esen¹, Bahtiyar Toz¹, Burak Erer¹, Sevil Kamali¹, Ahmet Gul¹, Lale Ocal² and Murat Inanc³, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Istanbul Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey, ³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical and serological manifestations. B-cell-targeted therapies have been promising new treatments for SLE.…
Abstract Number: 778 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 779 • 2016 ACR/ARHP Annual Meeting
Factors Determining Hydroxychloroquine Serum Levels in a Cohort of Chinese Patients with Systemic Lupus Erythematosus
Chi Chiu Mok¹, Ling Yin Ho² and Paul Jannetto³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic, Rochester, MN
Background/Purpose: To study the factors determining the hydroxychloroquine (HCQ) serum concentration in a cohort of Chinese patients with systemic lupus erythematosus (SLE). Methods: Consecutive patients…
Abstract Number: 780 • 2016 ACR/ARHP Annual Meeting
Belimumab Use in African-American Patients in an U.S. Academic Medical Center
Paloma Alejandro¹, Anjani Pillarisetty² and Christopher E. Collins³, ¹Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ²Internal Medicine, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ³MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC
Background/Purpose: Belimumab is an anti-BAFF monoclonal antibody approved for the treatment of auto-antibody positive patients with SLE. In two large phase 3 clinical trials, belimumab…
Abstract Number: 781 • 2016 ACR/ARHP Annual Meeting
The Use of Rituximab in Newly Diagnosed Systemic Lupus Erythematosus Patients: Long Term Steroid Saving Capacity and Clinical Effectiveness
Borja del Carmelo Gracia Tello Sr.¹, David A. Isenberg² and Amara Ezeonyeji³, ¹Internal Medicina, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, University College of London Hospital, London, London, United Kingdom
Background/Purpose: To assess the long term steroid saving capacity and clinical effectiveness of B-cell depletion therapy (BCDT) in newly diagnosed SLE patients. Methods: Sixteen female…
Abstract Number: 782 • 2016 ACR/ARHP Annual Meeting
Can We Identify Who Benefits from Mycophenolate Mofetil in Systemic Lupus Erythematosus? a Systematic Review
Claudia Mendoza Pinto^1,2, Carmelo Pirone³, Ben Parker⁴ and Ian N. Bruce⁵, ¹Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR, IMSS, Puebla, Mexico, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Rheumatology Unit, Sapienza University of Rome, Department of Internal Medicine and Medical Specialties,, Rome, Italy, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁵Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Mycophenolate mofetil (MMF) is widely used in the treatment of SLE however little is known about factors that may predict response or other outcomes…
Abstract Number: 783 • 2016 ACR/ARHP Annual Meeting
Review of SLE Cohort to Identify Predictors of Response to B Cell Depletion in Patients with Active SLE
Pedro Mota¹, Ashleigh Hennessey², Ada Ferenkeh-Koroma² and David A. Isenberg², ¹Internal Medicine, Hospital da Luz, Lisbon, Portugal, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: The use of Rituximab (RTX) has been documented via published cohort data from over 20 sites worldwide (1,2) demonstrating its useful role in the…
Abstract Number: 784 • 2016 ACR/ARHP Annual Meeting
Drivers of the SLE Responder Index (SRI) Endpoint in Clinical Trials of SLE
Kenneth C. Kalunian¹, Murray Urowitz², David A. Isenberg³, Joan T. Merrill⁴, Michelle Petri⁵, Richard Furie⁶, MaryAnn Morgan-Cox⁷, Rebecca Taha⁷, Maria Silk⁷ and Matthew D Linnik⁸, ¹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ²Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶North Shore University Hospital, Great Neck, NY, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Immunology, Lilly Biotechnology Center, San Diego, CA
Background/Purpose: SRI is a composite endpoint designed to ensure that clinical improvement (measured by SLEDAI) is not accompanied by deterioration in other organ systems (measured…
Abstract Number: 785 • 2016 ACR/ARHP Annual Meeting
What Is the Prevalence of Cognitive Impairment in Lupus and Which Instruments Are Used to Measure It? a Systematic Review and Meta-Analysis
Hanan Al Rayes¹, Chiara Tani², Marta Mosca², Jorge Medina-Rosas³, Ahmed Moustafa⁴, Panayiotis Lambiris⁵ and Zahi Touma¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ³Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine, Western University, London, ON, Canada, ⁵University Health Network, Toronto, ON, Canada
Background/Purpose: To systematically review literature on: 1) the prevalence of Cognitive Impairment (CI) in SLE patients in the presence or absence of neuropsychiatric involvement (NPSLE),…
Abstract Number: 786 • 2016 ACR/ARHP Annual Meeting
Complement Split Product iC3b and C3 Blood Levels Best Associate with Active and Clinically Meaningful Changes in SLE Disease Activity
Alfred Kim¹, Deepali Sen², Vibeke Strand³, Qiang John Fu⁴, Nancy Mathis¹, Robin Bruchas⁵, Nick Staten⁵, Martin Schmidt⁶, Paul Olson⁵, Chad Stiening⁵ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³Stanford University School of Medicine, Palo Alto, CA, ⁴Biostatistics, Saint Louis University, Saint Louis, MO, ⁵Kypha, Inc., Saint Louis, MO, ⁶Kypha, Inc., St. Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 787 • 2016 ACR/ARHP Annual Meeting
Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Measure Disease Severity in Discoid Lupus Erythematosus
Jenna K. Presto^1,2, Jessica S. Haber^1,2 and Victoria P. Werth^1,2, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Discoid lupus erythematosus (DLE) progresses to systemic lupus erythematosus (SLE) in up to 28% of cases. The Systemic Lupus International Collaborating Clinics (SLICC) SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].